Related Experiment Video
Updated: May 14, 2026

A Matrigel-Based Tube Formation Assay to Assess the Vasculogenic Activity of Tumor Cells
Published on: September 7, 2011
Vasculogenic mimicry is a prognostic factor for postoperative survival in patients with glioblastoma
Shi-Yong Wang1, Yi-Quan Ke, Guo-Hui Lu
1Department of Neurosurgery, Zhujiang Hospital, National Key Clinic Department, Neurosurgery Institute, Key Laboratory on Brain Function Repair and Regeneration of Guangdong, Southern Medical University, Gongye Road 253, Guangzhou 510282, China.
Abstract:
A previous report has confirmed the existence and clinical significance of vasculogenic mimicry (VM) in glioma. However, its conclusions about the negative clinical significance of VM in glioblastoma are based on a small group of patients and, thus, might be unconvincing. The aim of the present study was to reevaluate the clinical significance of VM in glioblastoma. Patients were classified as VM-positive or VM-negative according to CD34 and periodic acid-Schiff staining. The association between VM and the clinical characteristics of the patients was analyzed. Univariate and multivariate analyses were carried out to identify the independent prognostic factors for overall survival using the Cox regression hazard model. Survival times were estimated using the Kaplan-Meier method and compared using the log-rank test. Of all 86 glioblastomas, 23 were found to have VM. The presence of VM in glioblastoma was not associated with gender, age, Karnofsky performance status, hydrocephalus, tumor burden, microvessel density, tumor relapse, or the extent of tumor resection. The univariate and multivariate analyses revealed that VM is an independent prognostic factor for overall survival. The median survival time for patients with VM was 11.17 months compared with 16.10 months for those without VM (P = 0.017). In addition to VM, an age of 65 years or older, a KPS of 60 or less, a large tumor burden are significant prognostic factors for patient survival. Our data suggest that VM might be an independent adverse prognostic factor in newly diagnosed GBM, further prospective studies are needed to answer this question.
Insights
Vasculogenic mimicry (VM) is an independent prognostic factor in glioblastoma, negatively impacting patient survival. This study reevaluates VM
Area of Science:
- Neuro-oncology
- Cancer Biology
- Pathology
Background:
- Previous studies suggested vasculogenic mimicry (VM) has clinical significance in glioma.
- Limited patient cohorts in prior research may have weakened conclusions on VM's prognostic value in glioblastoma.
Purpose of the Study:
- To reevaluate the clinical significance of VM in glioblastoma.
- To determine if VM is an independent prognostic factor for overall survival in glioblastoma patients.
Main Methods:
- Classified 86 glioblastoma patients into VM-positive or VM-negative groups using CD34 and periodic acid-Schiff staining.
- Analyzed associations between VM and clinical characteristics.
- Employed univariate and multivariate Cox regression analyses and Kaplan-Meier survival estimates.
Main Results:
- VM was present in 23 of 86 glioblastomas and not associated with clinical characteristics like age, gender, or tumor burden.
- VM was identified as an independent prognostic factor for overall survival.
- Median survival was 11.17 months for VM-positive patients versus 16.10 months for VM-negative patients (P=0.017).
Conclusions:
- Vasculogenic mimicry may serve as an independent adverse prognostic factor in newly diagnosed glioblastoma.
- Age, Karnofsky Performance Status, and tumor burden also significantly impact glioblastoma patient survival.
- Further prospective studies are warranted to confirm VM's role as an adverse prognostic indicator.

